GSK PHARMA has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Sep-17* | 3 Jun-18* | 3 Sep-18* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 8,363 | 7,357 | 8,163 | 11.0% | -2.4% |
Other income | Rs m | 96 | 178 | 148 | -16.6% | 54.2% |
Turnover | Rs m | 8,459 | 7,534 | 8,311 | 10.3% | -1.7% |
Expenses | Rs m | 6,442 | 5,953 | 6,512 | 9.4% | 1.1% |
Gross profit | Rs m | 1,973 | 1,321 | 1,534 | 16.1% | -22.3% |
Depreciation | Rs m | 77 | 114 | 115 | 1.2% | 48.8% |
Interest | Rs m | 0 | 2 | 2 | 10.0% | 0.0% |
Profit before tax | Rs m | 1,991 | 1,383 | 1,565 | 13.1% | -21.4% |
Tax | Rs m | 688 | 497 | 557 | 12.0% | -19.1% |
Profit after tax | Rs m | 1,303 | 886 | 1,008 | 13.7% | -22.7% |
Gross profit margin | % | 23.6 | 18.0 | 18.8 | ||
Effective tax rate | % | 34.6 | 35.9 | 35.6 | ||
Net profit margin | % | 15.4 | 11.8 | 12.1 |
To see how GSK PHARMA has performed over the last eight quarters, please visit here.
Over the last one year, GSK PHARMA share price has moved up from Rs 1,217.9 to Rs 1,355.0, registering a Gain of Rs 137.1 or around 11.3%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,438.9 (down 0.5%). Over the last one year it has moved up from 14,047.3 to 14,438.9, a gain of 392 points (up 2.8%).
Overall, the S&P BSE SENSEX is up 4.6% over the year.
At the current price of Rs 1,355.0, the price to earnings (P/E) ratio of GSK PHARMA stands at 59.7 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 11.2 times.
| |
For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsWhat to do after every trade.
A high probability trade that worked to perfection for my subscribers.
This corner of the market could provide more returns than blue chips in 2020.
Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
I won't be surprised if these stocks repeat their 2002-2006 performance.
More
| |
Equitymaster requests your view! Post a comment on "GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!